EMEA-002320-PIP01-17-M03
Submitted by Anonymous (not verified) on 14 February 2024 - 14:37
EMEA-002320-PIP01-17-M03
Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline
Submitted by Anonymous (not verified) on 14 February 2024 - 14:27
Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline
Opinion/decision on a Paediatric investigation plan (PIP): Takhzyro, lanadelumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Other, PIP number: P/0037/2023
Submitted by Anonymous (not verified) on 14 February 2024 - 13:34
Opinion/decision on a Paediatric investigation plan (PIP): Takhzyro, lanadelumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Other, PIP number: P/0037/2023
EMEA-003212-PIP01-22
Submitted by Anonymous (not verified) on 14 February 2024 - 13:11
EMEA-003212-PIP01-22
EMEA-003207-PIP01-22
Submitted by Anonymous (not verified) on 14 February 2024 - 13:02
EMEA-003207-PIP01-22
EMEA-003177-PIP01-21
Submitted by Anonymous (not verified) on 14 February 2024 - 12:50
EMEA-003177-PIP01-21
EMEA-002283-PIP01-17-M04
Submitted by Anonymous (not verified) on 14 February 2024 - 10:45
EMEA-002283-PIP01-17-M04
EMEA-003122-PIP01-21-M01
Submitted by Anonymous (not verified) on 14 February 2024 - 10:11
EMEA-003122-PIP01-21-M01
European Medicines Agency mid-year report 2022 (January-June 2022)
Submitted by Anonymous (not verified) on 14 February 2024 - 10:10
European Medicines Agency mid-year report 2022 (January-June 2022)
Annual activity report 2022
Submitted by Anonymous (not verified) on 14 February 2024 - 10:00
Annual activity report 2022